

S/N 10/697,995

PATENT


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	REILLY ET AL.	Examiner:	UNKNOWN
Serial No.:	10/697,995	Group Art Unit:	1645
Filed:	OCTOBER 30, 2003	Docket No.:	11669.195USU1
Confirmation No.:	7395	Customer No.:	23552
Title:	METHODS AND COMPOSITIONS FOR INCREASING ANTIBODY PRODUCTION		

CERTIFICATE UNDER 37 CFR 1.10:

"Express Mail" mailing label number: EV 371503619 US
Date of Deposit: October 20, 2004

I hereby certify that this paper or fee is being deposited with the U.S. Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


By: _____
Name: Sheryl A. Boerboom

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (37 C.F.R. § 1.97(b))

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

With regard to the above-identified application, the items of information listed on the enclosed Form 1449 are brought to the attention of the Examiner.

This statement should be considered because it is submitted before the mailing date of a first Office Action on-the-merits. Accordingly, no fee is due for consideration of the items listed on the enclosed Form 1449.

Because this application was filed after June 30, 2003, copies have been provided only for the foreign patent documents or "Other documents" listed on the enclosed Form 1449 that have not previously been cited by or submitted to the U.S. Patent and Trademark Office.

No representation is made that a reference is "prior art" within the meaning of 35 U.S.C. §§ 102 and 103 and Applicants reserve the right, pursuant to 37 C.F.R. § 1.131 or otherwise, to establish that the reference(s) are not "prior art." Moreover, Applicant(s) do not represent that a

reference has been thoroughly reviewed or that any relevance of any portion of a reference is intended.


Consideration of the items listed is respectfully requested. Pursuant to the provisions of M.P.E.P. 609, it is requested that the Examiner return a copy of the attached Form 1449, marked as being considered and initialed by the Examiner, to the undersigned with the next official communication.

Please charge any additional fees or credit any overpayment to Deposit Account No. 13-2725.


Respectfully submitted,


MERCHANT & GOULD P.C.
P.O. Box 2903
Minneapolis, Minnesota 55402-0903
(612) 332-5300

Date: October 20, 2001



Katherine M. Kowalchyk
Reg. No. 36,848
KMK:sab



 FORM 1449* INFORMATION DISCLOSURE STATEMENT IN AN APPLICATION (Use several sheets if necessary)	Docket Number: 11669.195USU1	Application Number: 10/697,995
	Applicant: REILLY ET AL.	
	Filing Date: 10/30/2003	Group Art Unit: 1645

U.S. PATENT DOCUMENTS						
EXAMINER INITIAL	DOCUMENT NO.	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	4,816,567	03/28/1989	Cabilly et al.			
	5,264,365	11/23/1993	Georgiou et al.			
	5,264,586	11/23/1993	Nicolaou et al.			
	5,348,876	09/20/1994	Michaelsen et al.			
	5,500,362	03/19/1996	Robinson et al.			
	5,508,192	04/16/1996	Georgiou et al.			
	5,585,097	12/17/1996	Bolt et al.			
	5,624,821	04/29/1997	Winter et al.			
	5,639,635	06/17/1997	Joly et al.			
	5,648,237	07/15/1997	Carter			
	5,821,337	10/13/1998	Carter et al.			
	5,840,523	11/24/1998	Simmons et al.			
	5,854,027	12/29/1998	Steipe et al.			
	5,892,019	04/06/1999	Schlom et al.			
	6,027,888	02/22/2000	Georgiou et al.			
	6,083,715	07/04/2000	Georgiou et al.			
	6,165,745	12/26/2000	Ward et al.			
	6,455,279 B1	09/24/2002	Ambrosius et al.			
	6,602,688 B1	08/05/2003	Opper et al.			
FOREIGN PATENT DOCUMENTS						
	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES
	WO 92/22583	12/23/1992	PCT			
	WO 94/29531	12/22/1994	PCT			
	WO 95/14779	06/01/1995	PCT			

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT		Docket Number: 11669.195USU1	Application Number: 10/697,995
IN AN APPLICATION (Use several sheets if necessary)		Applicant: REILLY ET AL.	
		Filing Date: 10/30/2003	Group Art Unit: 1645

	WO 99/25378	05/27/1999	PCT				
	WO 99/51642	10/14/1999	PCT				
	WO 99/64460	12/16/1999	PCT				
	WO 02/056910	07/25/2002	PCT				
	WO 02/061090	08/08/2002	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	Adlersberg, "The Immunoglobulin Hinge (Interdomain) Region", <i>Ric. Clin. Lab.</i> , 6(3):191-205 (1976)
	Arie et al., "Chaperone function of FkpA, a heat shock prolyl isomerase, in the periplasm of <i>Escherichia coli</i> ", <i>Molecular Microbiology</i> , 39(1):199-210 (2001)
	Armour et al., "Recombinant human IgG molecules lacking Fc γ receptor I binding and monocyte triggering activities", <i>Eur. J. Immunol.</i> , 29:2613-2624 (1999)
	Barbas et al., "In vitro evolution of a neutralizing human antibody to human immunodeficiency virus type 1 to enhance affinity and broaden strain cross-reactivity", <i>Proc. Natl. Acad. Sci. USA</i> , 91:3809-3813 (1994)
	Bloom et al., "Intrachain disulfide bond in the core hinge region of human IgG4", <i>Protein Science</i> , 6:407-415 (1997)
	Bothmann et al., "The Periplasmic <i>Escherichia coli</i> Peptidylprolyl cis,trans-Isomerase FkpA", <i>Journal of Biological Chemistry</i> , 275(22):17100-17105 (2000)
	Brekke et al., "Activation of complement by an IgG molecule without a genetic hinge", <i>Nature</i> , 363:628-630 (1993)
	Capel et al., "Heterogeneity of Human IgG Fc Receptors", <i>Immunomethods</i> , 4:25-34 (1994)
	Carter et al., "High Level <i>Escherichia Coli</i> Expression and Production of a Bivalent Humanized Antibody Fragment", <i>Bio/Technology</i> , 10:163-167 (1992)
	Carter et al., "Humanization of an anti-p185 ^{HER2} antibody for human cancer therapy", <i>Proc. Natl. Acad. Sci. USA</i> , 89:4285-4289 (1992)
	Chamow et al., "A Humanized, Bispecific Immunoadhesin-Antibody that Retargets CD3 $^{+}$ Effectors to Kill HIV-1-Infected Cells", <i>J. Immunol.</i> , 153:4268-4280 (1994)
	Chang et al., "High-level secretion of human growth hormone by <i>Escherichia coli</i> ", <i>Gene</i> , 55:189-196 (1987)
	Chen et al., "Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen", <i>J. Mol. Biol.</i> , 293:865-881 (1999)
	Chen et al., "Chaperone Activity of DsbC", <i>Journal of Biological Chemistry</i> , 274(28):19601-19605 (1999)
	Chothia et al., "Canonical Structures for the Hypervariable Regions", <i>J. Mol. Biol.</i> , 196:901-917 (1987)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT		Docket Number: 11669.195USU1	Application Number: 10/697,995
IN AN APPLICATION (Use several sheets if necessary)		Applicant: REILLY ET AL.	
		Filing Date: 10/30/2003	Group Art Unit: 1645

	Clynes et al., "Fc receptors are required in passive and active immunity to melanoma", <i>Proc. Natl. Acad. Sci. USA</i> , 95:652-656 (1998)
	Daëron et al., "Fc Receptor Biology", <i>Annu. Rev. Immunol.</i> , 15:203-234 (1997)
	de Haas et al., "Fc γ receptors of phagocytes", <i>J. Lab. Clin. Med.</i> , 126:330-341 (1995)
	Duncan et al., "The binding site for Clq on IgG", <i>Nature</i> , 232:738-740 (1988)
	Friend et al., "Phase I Study of an Engineered Aglycosylated Humanized CD3 Antibody in Renal Transplant Rejection", <i>Transplantation</i> , 68:1632-1637 (1999)
	Guyer et al., "Immunoglobulin Binding by Mouse Intestinal Epithelial Cell Receptors", <i>J. Immunol.</i> , 117:587-593 (1976)
	Hara et al., "Overproduction of Penicillin-Binding Protein 7 Suppresses Thermosensitive Growth Defect at Low Osmolarity due to an spr Mutation of <i>Escherichia coli</i> ", <i>Microbial Drug Resistance</i> , 2(1):63-72 (1996)
	Hawkins et al., "Selection of Phage Antibodies by Binding Affinity: Mimicking Affinity Maturation", <i>J. Mol. Biol.</i> , 226:889-896 (1992)
	Humphreys et al., "Formation of dimeric Fabs in <i>Escherichia coli</i> : effect of hinge size and isotype, presence of interchain disulphide bond, Fab' expression levels, tail piece sequences and growth conditions", <i>J. Immunol. Methods</i> , 209:193-202 (1997)
	Isaacs et al., "A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans", <i>Clin. Exp. Immunol.</i> , 106:427-433 (1996)
	Jackson et al., "In Vitro Antibody Maturation: Improvement of a High Affinity, Neutralizing Antibody Against IL-1 β ", <i>J. Immunol.</i> , 154(7):3310-3319 (1995)
	Joly et al., "Overexpression of <i>Escherichia coli</i> oxidoreductases increases recombinant insulin-like growth factor-I accumulation", <i>Proc. Natl. Acad. Sci. USA</i> , 95:2773-2777 (1998)
	Jones et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse", <i>Nature</i> , 321:522-525 (1986)
	Kelley et al., "Analysis of the Factor VIIa Binding Site on Human Tissue Factor: Effects of Tissue Factor Mutations on the Kinetics and Thermodynamics of Binding", <i>Biochemistry</i> , 10383-10392 (1995)
	Kikuchi et al., "The nucleotide sequence of the promoter and the amino-terminal region of alkaline phosphatase structural gene (phoA) of <i>Escherichia coli</i> ", <i>Nucleic Acids Res.</i> , 9:5671-5678 (1981)
	Kim et al., "Localization of the site of the murine IgG1 molecule that is involved in binding to the murine intestinal Fc receptor", <i>J. Immunol.</i> , 24:2429-2434 (1994)
	Kim et al., "Evidence that the Hinge Region Plays a Role in Maintaining Serum Levels of the Murine IgG1 Molecule", <i>Mol. Immunol.</i> , 32(7):467-475 (1995)
	Kipriyanov et al., "Generation of Recombinant Antibodies", <i>Mol. Biotech.</i> , 12:173-201 (1999)
	Lee et al., "Characterization of the Gene Encoding Heat-Stable Toxin II and Preliminary Molecular Epidemiological Studies of Enterotoxigenic <i>Escherichia coli</i> Heat-Stable Toxin II Producers", <i>Infect. Immun.</i> , 42(1):264-268 (1983)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT		Docket Number: 11669.195USU1	Application Number: 10/697,995
IN AN APPLICATION (Use several sheets if necessary)		Applicant: REILLY ET AL.	
		Filing Date: 10/30/2003	Group Art Unit: 1645

	Marks et al., "By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling", <i>Bio/Technology</i> , 10:779-783 (1992)
	Merchant et al., "An efficient route to human bispecific IgG", <i>Nat. Biotech.</i> , 16:677-681 (1998)
	Morrison et al., "Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region dimmers", <i>Proc. Natl. Acad. Sci USA</i> , 81(21):6851-6855 (1984)
	Peters et al., "Vascular endothelial growth factor receptor expression during embryogenesis and tissue repair suggests a role in endothelial differentiation and blood vessel growth", <i>Proc. Natl. Acad. USA</i> , 90:8915-8919 (1993)
	Picken et al., "Nucleotide Sequence of the Gene for Heat-Stable Enterotoxin II of <i>Escherichia coli</i> ", <i>Infect. Immun.</i> , 42(1):269-275 (1983)
	Plückthun et al., "New protein engineering approaches to multivalent and bispecific antibody fragments", <i>Immunotech</i> , 3:83-105 (1997)
	Plückthun et al., "Producing antibodies in <i>Escherichia coli</i> : from PCR to fermentation", <i>Antibody Engineering: A Practical Approach</i> , Oxford Press, Chap. 10, pp. 203-252 (1996)
	Plückthun, "Antibodies from <i>Escherichia coli</i> ", <i>The Pharmacol. of Monoclonal Antibodies, Handbook of Exp. Pharmacology</i> , 3:269-315 (1994)
	Presta et al., "Humanization of an Anti-Bascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders", <i>Cancer Res.</i> , 57:4593-4599 (1997)
	Presta et al., "Humanization of an Antibody Directed Against IgE", <i>J. Immunol.</i> , 151(5):2623-2632 (1993)
	Presta et al., "Generation of a Humanized, High Affinity Anti-tissue Factor Antibody for Use as a Novel Antithrombotic Therapeutic", <i>Thromb. Haemost.</i> , 85:379-389 (2001)
	Presta, "Antibody Engineering", <i>Curr. Op. Struct. Biol.</i> , 2:593-596 (1992)
	Proba et al., "Functional antibody single-chain fragments from the cytoplasm of <i>Escherichia coli</i> : influence of thioredoxin reductase (TrxB)", <i>Gene</i> , 159:203-207 (1995)
	Ramm et al., "The Periplasmic <i>Escherichia coli</i> Peptidylprolyl cis,trans-Isomerase FkpA", <i>J. Mol. Biol.</i> , 275(22):17106-17113 (2000)
	Ravetch et al., "Fc Receptors", <i>Annu. Rev. Immunol.</i> , 9:457-492 (1991)
	Reddy et al., "Elimination of Fc Receptor-Dependent Effector Functions of a Modified IgG4 Monoclonal Antibody to Human CD4", <i>J. Immunol.</i> , 164:1925-1933 (2000)
	Riechmann et al., "Reshaping human antibodies for therapy", <i>Nature</i> , 332:323-327 (1988)
	Schier et al., "Identification of functional and structural amino-acid residues by parsimonious mutagenesis", <i>Gene</i> , 169:147-155 (1995)
	Scholtissek et al., "A cloning cartridge of γ t ₀ terminator", <i>Nucleic Acids Res.</i> , 15:3185 (1987)
	Sheilds et al., "High Resolution Mapping of the Binding Site on Human IgG1 for Fc γ R1, Fc γ RII, Fc γ RIII, and FcRn and Design of IgG1 Variants with Improved Binding to the Fc γ R", <i>Biol. Chem.</i> , 276, 6591-6604 (2001)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	

FORM 1449* INFORMATION DISCLOSURE STATEMENT		Docket Number: 11669.195USU1	Application Number: 10/697,995
IN AN APPLICATION (Use several sheets if necessary)		Applicant: REILLY ET AL.	
		Filing Date: 10/30/2003	Group Art Unit: 1645

		Siebenlist et al., "E. coli RNA Polymerase Interacts Homologously with Two Different Promoters", <i>Cell</i> , 20:269-281 (1980)
		Simmons et al., "Expression of full-length immunoglobulins in <i>Escherichia coli</i> " rapid and efficient production of aglycosylated antibodies", <i>J. Immunol. Methods</i> , 263:133-147 (2002)
		Simmons et al., "Translational level is a critical factor for the secretion of heterologous proteins in <i>Escherichia coli</i> ", <i>Nature Biotechnology</i> , 14:629-634 (1996)
		Sims et al., "A Humanized CD18 Antibody Can Block Function without Cell Destruction", <i>J. Immunol.</i> , 151:2296-2308 (1993)
		Sutcliffe, "Complete Nucleotide Sequence of the <i>Escherichia coli</i> Plasmid pBR322", <i>DNA: Replication and Recombination, Cold Spring Harbor Symposia on Quantitative Biology</i> , Cold Spring Harbor Laboratory, Vol. XLIII:77-90 (1979)
		Thompson et al., "A fully human antibody neutralizing biologically active human TGF β 2 for use in therapy", <i>J. Immunol Meth</i> , 227:17-29 (1999)
		Verhoeven et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity", <i>Science</i> , 239:1534-1536 (1988)
		Yanofsky et al., "The complete nucleotide sequence of the tryptophan operon of <i>Escherichia coli</i> ", <i>Nucleic Acids Res.</i> , 9:6647-6668 (1981)
		Yansura et al., "Nucleotide Sequence Selection for Increased Expression of Heterologous Genes in <i>Escherichia coli</i> ", <i>Methods: A companion to Methods in Enzymology</i> , 4:151-158 (1992)
		Yelton et al., "Affinity Maturation of the BR96 Anti-Carcinoma Antibody by Codon-Based Mutagenesis", <i>J. Immunol.</i> , 155:1994-2004 (1995)

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form for next communication to the Applicant.	